Mga Batayang Estadistika
| LEI | 529900QR4WAPYY0CBF25 |
| CIK | 1654151 |
SEC Filings
All companies that sell securities in the United States must register with the Securities and Exchange Commission (SEC) and file reports on a regular basis.
These reports include company annual reports (10K, 10Q), news updates (8K), investor presentations (found in 8Ks), insider trades (form 4), ownership reports (13D, and 13G), and reports related to the specific securities sold, such as registration statements and prospectus. This page shows recent SEC filings related to Deciphera Pharmaceuticals, Inc.
SEC Filings (Chronological Order)
Halaman ini menyediakan daftar lengkap dan kronologis dari Pengajuan SEC, tidak termasuk pengajuan kepemilikan yang kami sediakan di tempat lain.
| November 14, 2024 |
DCPH / Deciphera Pharmaceuticals, Inc. / ARMISTICE CAPITAL, LLC Passive Investment UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 SCHEDULE 13G/A Under the Securities Exchange Act of 1934 (Amendment No. |
|
| June 21, 2024 |
15-12G UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 15 CERTIFICATION AND NOTICE OF TERMINATION OF REGISTRATION UNDER SECTION 12(g) OF THE SECURITIES EXCHANGE ACT OF 1934 OR SUSPENSION OF DUTY TO FILE REPORTS UNDER SECTIONS 13 AND 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934. Commission File Number 001-38219 Deciphera Pharmaceuticals, Inc. (Exact name of registrant a |
|
| June 11, 2024 |
As filed with the Securities and Exchange Commission on June 11, 2024 As filed with the Securities and Exchange Commission on June 11, 2024 Registration No. |
|
| June 11, 2024 |
SC TO-T/A UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE TO Tender Offer Statement Under Section 14(d)(1) or 13(e)(1) of the Securities Exchange Act of 1934 (Amendment No. 3) DECIPHERA PHARMACEUTICALS, INC. (Name of Subject Company) TOPAZ MERGER SUB, INC. a wholly owned subsidiary of ONO PHARMACEUTICAL CO., LTD. (Names of Filing Persons – Offeror) Common Stock, Pa |
|
| June 11, 2024 |
AMENDED AND RESTATED CERTIFICATE OF INCORPORATION DECIPHERA PHARMACEUTICALS, INC. June 11, 2024 EX-3.1 Exhibit 3.1 AMENDED AND RESTATED CERTIFICATE OF INCORPORATION OF DECIPHERA PHARMACEUTICALS, INC. June 11, 2024 FIRST: The name of the corporation is Deciphera Pharmaceuticals, Inc. (the “Corporation”). SECOND: The address of the Corporation’s registered office in the State of Delaware is The Corporation Trust Company, 1209 Orange Street, City of Wilmington, County of New Castle, Delaware 19 |
|
| June 11, 2024 |
EX-99.(a)(5)(iv) Exhibit (a)(5)(iv) Press Release Ono Announces Results of Tender Offer to Acquire Deciphera Pharmaceuticals and Completion of Acquisition of Deciphera (a Wholly Owned Subsidiary of Ono) Osaka, Japan and Waltham, Massachusetts, June 11, 2024 – Ono Pharmaceutical Co., Ltd. (Chairman and CEO: Gyo Sagara, “Ono”) today announced that it has successfully completed the tender offer, pre |
|
| June 11, 2024 |
As filed with the Securities and Exchange Commission on June 11, 2024 As filed with the Securities and Exchange Commission on June 11, 2024 Registration No. |
|
| June 11, 2024 |
As filed with the Securities and Exchange Commission on June 11, 2024 As filed with the Securities and Exchange Commission on June 11, 2024 Registration No. |
|
| June 11, 2024 |
As filed with the Securities and Exchange Commission on June 11, 2024 As filed with the Securities and Exchange Commission on June 11, 2024 Registration No. |
|
| June 11, 2024 |
SECOND AMENDED AND RESTATED DECIPHERA PHARMACEUTICALS, INC. June 11, 2024 * * * * * ARTICLE 1 EX-3.2 Exhibit 3.2 SECOND AMENDED AND RESTATED BYLAWS OF DECIPHERA PHARMACEUTICALS, INC. June 11, 2024 * * * * * ARTICLE 1 OFFICES Section 1.1 Registered Office. The registered office of Deciphera Pharmaceuticals, Inc. (as such name may be changed in accordance with applicable law, the “Corporation”) in the State of Delaware, and the name of the Corporation’s registered agent at such address, shal |
|
| June 11, 2024 |
As filed with the Securities and Exchange Commission on June 11, 2024 As filed with the Securities and Exchange Commission on June 11, 2024 Registration No. |
|
| June 11, 2024 |
As filed with the Securities and Exchange Commission on June 11, 2024 As filed with the Securities and Exchange Commission on June 11, 2024 Registration No. |
|
| June 11, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): June 11, 2024 Deciphera Pharmaceuticals, Inc. (Exact name of registrant as specified in its charter) Delaware 001-38219 30-1003521 (State or other jurisdiction of incorporation) (Comm |
|
| June 11, 2024 |
As filed with the Securities and Exchange Commission on June 11, 2024 As filed with the Securities and Exchange Commission on June 11, 2024 Registration No. |
|
| June 11, 2024 |
As filed with the Securities and Exchange Commission on June 11, 2024 As filed with the Securities and Exchange Commission on June 11, 2024 Registration No. |
|
| June 11, 2024 |
SC 14D9/A UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14D-9 (Rule 14d-101) (Amendment No. 3) SOLICITATION/RECOMMENDATION STATEMENT UNDER SECTION 14(d)(4) OF THE SECURITIES EXCHANGE ACT OF 1934 Deciphera Pharmaceuticals, Inc. (Name of Subject Company) Deciphera Pharmaceuticals, Inc. (Name of Persons Filing Statement) Common Stock, par value $0.01 per share (Titl |
|
| June 11, 2024 |
As filed with the Securities and Exchange Commission on June 11, 2024 As filed with the Securities and Exchange Commission on June 11, 2024 Registration No. |
|
| June 11, 2024 |
As filed with the Securities and Exchange Commission on June 11, 2024 As filed with the Securities and Exchange Commission on June 11, 2024 Registration No. |
|
| June 3, 2024 |
SC 14D9/A UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14D-9 (Rule 14d-101) (Amendment No. 2) SOLICITATION/RECOMMENDATION STATEMENT UNDER SECTION 14(d)(4) OF THE SECURITIES EXCHANGE ACT OF 1934 Deciphera Pharmaceuticals, Inc. (Name of Subject Company) Deciphera Pharmaceuticals, Inc. (Name of Persons Filing Statement) Common Stock, par value $0.01 per share (Titl |
|
| May 28, 2024 |
EX-99.(b)(1) Exhibit (b)(1) Special Overdraft Agreement Ono Pharmaceutical Co., Ltd. (hereinafter referred to as the “Borrower”) and Sumitomo Mitsui Banking Corporation (hereinafter referred to as the “Lender”) (hereinafter referred to as the “Lender”) have agreed to the following terms and conditions, in addition to the terms and conditions of the “Bank Transaction Agreement” separately agreed up |
|
| May 28, 2024 |
Overdraft (Dedicated Account) Agreement EX-99.(b)(2) Exhibit (b)(2) Overdraft (Dedicated Account) Agreement May 31, 2024 To MUFG Bank, Ltd. (“Bank”) Address The person himself Seal I hereby confirm and agree to the following terms and conditions in addition to the terms and conditions of the separately submitted Banking Transaction Agreement in connection with the overdraft (dedicated account) transactions using my current account |
|
| May 28, 2024 |
SC TO-T/A UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE TO Tender Offer Statement Under Section 14(d)(1) or 13(e)(1) of the Securities Exchange Act of 1934 (Amendment No. 2) DECIPHERA PHARMACEUTICALS, INC. (Name of Subject Company) TOPAZ MERGER SUB, INC. a wholly owned subsidiary of ONO PHARMACEUTICAL CO., LTD. (Names of Filing Persons – Offeror) Common Stock, Pa |
|
| May 22, 2024 |
SC 14D9/A UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14D-9 (Rule 14d-101) Solicitation/Recommendation Statement Under Section 14(d)(4) of the Securities Exchange Act of 1934 (Amendment No. 1) Deciphera Pharmaceuticals, Inc. (Name of Subject Company) Deciphera Pharmaceuticals, Inc. (Name of Persons Filing Statement) Common Stock, par value $0.01 per share (Titl |
|
| May 22, 2024 |
May 22, 2024 VIA EDGAR U.S. Securities and Exchange Commission Division of Corporation Finance Office of Mergers and Acquisitions 100 F Street, N.E. Washington, D.C. 20549 Attn: Eddie Kim David Plattner Re: Deciphera Pharmaceuticals, Inc. Schedule 14D-9 filed May 13, 2024 File No. 005-90130 Ladies and Gentlemen: This letter is submitted on behalf of Deciphera Pharmaceuticals, Inc. (the “Company”) |
|
| May 22, 2024 |
SC TO-T/A UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE TO Tender Offer Statement Under Section 14(d)(1) or 13(e)(1) of the Securities Exchange Act of 1934 (Amendment No. 1) DECIPHERA PHARMACEUTICALS, INC. (Name of Subject Company) TOPAZ MERGER SUB, INC. a wholly owned subsidiary of ONO PHARMACEUTICAL CO., LTD. (Names of Filing Persons – Offeror) Common Stock, Pa |
|
| May 13, 2024 |
Exhibit 107 Calculation of Filing Fee Tables SC TO-T (Form Type) Deciphera Pharmaceuticals, Inc. |
|
| May 13, 2024 |
EX-99.(a)(1)(iv) Exhibit (a)(1)(iv) Offer to Purchase for Cash All Outstanding Shares of Common Stock of Deciphera Pharmaceuticals, Inc. at $25.60 net per share in cash, pursuant to the Offer to Purchase, dated May 13, 2024, by Topaz Merger Sub, Inc., a wholly-owned subsidiary of ONO PHARMACEUTICAL CO., LTD. THE OFFER AND WITHDRAWAL RIGHTS WILL EXPIRE AT ONE MINUTE AFTER 11:59 P.M., NEW YORK CITY |
|
| May 13, 2024 |
FORM OF TENDER AND SUPPORT AGREEMENT Exhibit (d)(2) FORM OF TENDER AND SUPPORT AGREEMENT This TENDER AND SUPPORT AGREEMENT (this “Agreement”), dated as of April 29, 2024, is entered into by and among ONO PHARMACEUTICAL CO. |
|
| May 13, 2024 |
Exhibit (a)(1)(ii) Letter of Transmittal to tender Shares of Common Stock of DECIPHERA PHARMACEUTICALS, INC. |
|
| May 13, 2024 |
Exhibit (a)(1)(v) Offer to Purchase for Cash All Outstanding Shares of Common Stock of Deciphera Pharmaceuticals, Inc. |
|
| May 13, 2024 |
Table of Contents Exhibit (a)(1)(i) OFFER TO PURCHASE All Outstanding Shares of Common Stock of DECIPHERA PHARMACEUTICALS, INC. |
|
| May 13, 2024 |
Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14D-9 (Rule 14d-101) Solicitation/Recommendation Statement Under Section 14(d)(4) of the Securities Exchange Act of 1934 Deciphera Pharmaceuticals, Inc. (Name of Subject Company) Deciphera Pharmaceuticals, Inc. (Name of Persons Filing Statement) Common Stock, par value $0.01 per share (Title of Class |
|
| May 13, 2024 |
Exhibit (d)(3) EXECUTION COPY TENDER AND SUPPORT AGREEMENT This TENDER AND SUPPORT AGREEMENT (this “Agreement”), dated as of April 29, 2024, is entered into by and among ONO PHARMACEUTICAL CO. |
|
| May 13, 2024 |
Project Topaz Commitment Letter Exhibit (b) Execution Version CONFIDENTIAL April 29, 2024 Ono Pharmaceutical Co. |
|
| May 13, 2024 |
Exhibit (a)(1)(iii) NOTICE OF GUARANTEED DELIVERY to Tender Shares of Common Stock of Deciphera Pharmaceuticals, Inc. |
|
| May 13, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE TO Tender Offer Statement Under Section 14(d)(1) or 13(e)(1) of the Securities Exchange Act of 1934 DECIPHERA PHARMACEUTICALS, INC. (Name of Subject Company) TOPAZ MERGER SUB, INC. a wholly–owned subsidiary of ONO PHARMACEUTICAL CO., LTD. (Names of Filing Persons – Offeror) Common Stock, Par Value $0.01 Per Share (Tit |
|
| May 13, 2024 |
Exhibit (d)(4) EXECUTION COPY PERSONAL AND CONFIDENTIAL March 8, 2024 Ono Pharmaceutical Co. |
|
| May 13, 2024 |
Exhibit (a)(1)(vi) SUMMARY ADVERTISEMENT This announcement is neither an offer to purchase nor a solicitation of an offer to sell Shares (as defined below). |
|
| May 10, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2024 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number: 0 |
|
| May 6, 2024 |
Investor Presentation Script dated April 30, 2024. EX-99.2 Exhibit 99.2 ONO PHARMACEUTICAL CO., LTD. Briefing on the conclusion of the acquisition agreement for Deciphera Pharmaceuticals in the United States April 30, 2024 [Number of Speakers] 4 Gyo Sagara Representative Director, Chairman of the Board and Chief Executive Officer Toichi Takino Representative Director, President and Chief Operating Officer Masayuki Tanigawa Corporate Officer, Execu |
|
| May 6, 2024 |
Investor Presentation dated April 30, 2024. EX-99.1 Exhibit 99.1 Merger Agreement with Deciphera Pharmaceuticals April 30, 2024 Cautionary Note Regarding Forward-Looking Statements This communication relates to ONO Pharmaceutical co., ltd. (“ONO”), Deciphera Pharmaceuticals, Inc (“Deciphera”) and the proposed acquisition of Deciphera by ONO (the “Proposed Transaction”) and includes express or implied forward-looking statements about the Pro |
|
| May 6, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE TO Tender Offer Statement Under Section 14(d)(1) or 13(e)(1) of the Securities Exchange Act of 1934 DECIPHERA PHARMACEUTICALS, INC. (Name of Subject Company) TOPAZ MERGER SUB, INC. a wholly owned subsidiary of ONO PHARMACEUTICAL CO., LTD. (Names of Filing Persons – Offeror) Common Stock, Par Value $0.01 Per Share (Tit |
|
| April 30, 2024 |
EX-99.1 Exhibit 99.1 ONO Enters into a Definitive Agreement to Acquire Deciphera Pharmaceuticals Osaka, Japan and Waltham, Massachusetts, April 30, 2024 – ONO Pharmaceutical, Co., Ltd., (TSE: 4528, Representative Director, Chairman of the Board and Chief Executive Officer: Gyo Sagara, “ONO”) and Deciphera Pharmaceuticals, Inc. (NASDAQ: DCPH, Chief Executive Officer: Steven L. Hoerter, “Deciphera”) |
|
| April 30, 2024 |
EX-99.3 Exhibit 99.3 ONO Enters into a Definitive Agreement to Acquire Deciphera Pharmaceuticals Osaka, Japan and Waltham, Massachusetts, April 30, 2024 – ONO Pharmaceutical, Co., Ltd., (TSE: 4528, Representative Director, Chairman of the Board and Chief Executive Officer: Gyo Sagara, “ONO”) and Deciphera Pharmaceuticals, Inc. (NASDAQ: DCPH, Chief Executive Officer: Steven L. Hoerter, “Deciphera”) |
|
| April 30, 2024 |
SC14D9C UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14D-9 (Rule 14d-101) SOLICITATION/RECOMMENDATION STATEMENT UNDER SECTION 14(d)(4) OF THE SECURITIES EXCHANGE ACT OF 1934 Deciphera Pharmaceuticals, Inc. (Name of Subject Company) Deciphera Pharmaceuticals, Inc. (Name of Person(s) Filing Statement) COMMON STOCK, PAR VALUE $0.01 PER SHARE (Title of Class of Secu |
|
| April 30, 2024 |
EX-99.1 Exhibit 99.1 On April 29, 2024 (after 5:30 pm EST), Deciphera Pharmaceuticals, Inc. (“Deciphera”) and its President and Chief Executive Officer Steven L. Hoerter made the following announcements via LinkedIn regarding the planned cash tender offer (the “Offer”) by Topaz Merger Sub, Inc., a Delaware corporation (“Merger Sub”) and a wholly owned subsidiary of Ono Pharmaceutical Co., Ltd., a |
|
| April 30, 2024 |
SC TO-C UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE TO Tender Offer Statement Under Section 14(d)(1) or 13(e)(1) of the Securities Exchange Act of 1934 DECIPHERA PHARMACEUTICALS, INC. (Name of Subject Company) TOPAZ MERGER SUB, INC. a wholly owned subsidiary of ONO PHARMACEUTICAL CO., LTD. (Names of Filing Persons – Offeror) Common Stock, Par Value $0.01 Per Sh |
|
| April 30, 2024 |
Exhibit 99.2: Posting by the Company on X on April 29, 2024 (after 5:30 p.m. EST) EX-99.2 Exhibit 99.2 On April 29, 2024 (after 5:30 pm EST), Deciphera Pharmaceuticals, Inc. (“Deciphera”) made the following announcement via X regarding the planned cash tender offer (the “Offer”) by Topaz Merger Sub, Inc., a Delaware corporation (“Merger Sub”) and a wholly owned subsidiary of Ono Pharmaceutical Co., Ltd., a Japanese company (kabushiki kaishi) (“Ono”), to acquire all of the issue |
|
| April 29, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14D-9 (Rule 14d-101) SOLICITATION/RECOMMENDATION STATEMENT UNDER SECTION 14(d)(4) OF THE SECURITIES EXCHANGE ACT OF 1934 Deciphera Pharmaceuticals, Inc. (Name of Subject Company) Deciphera Pharmaceuticals, Inc. (Name of Person(s) Filing Statement) COMMON STOCK, PAR VALUE $0.01 PER SHARE (Title of Class of Securities) |
|
| April 29, 2024 |
Exhibit 2.1 AGREEMENT AND PLAN OF MERGER by and among ONO PHARMACEUTICAL CO., LTD., TOPAZ MERGER SUB, INC. and DECIPHERA PHARMACEUTICALS, INC. Dated as of April 29, 2024 TABLE OF CONTENTS ARTICLE 1 DEFINITIONS 2 Section 1.1. Definitions 2 ARTICLE 2 THE OFFER 15 Section 2.1. Tender Offer 15 Section 2.2. Actions of Parent and Merger Sub 18 Section 2.3. Actions of the Company 19 ARTICLE 3 THE MERG |
|
| April 29, 2024 |
Exhibit 99.4: Deciphera Email to certain stakeholders of the Company on April 29, 2024 Exhibit 99.4 Dear Valued Partner, I’m reaching out to share some exciting news about Deciphera – we have reached an agreement to be acquired by ONO Pharmaceutical, a global healthcare company dedicated to the fight against disease and pain. This combination marks the beginning of an exciting next chapter for Deciphera, one that we believe will advance our work to bring important medicines to more |
|
| April 29, 2024 |
Exhibit 99.5: Deciphera Email to certain suppliers and vendors of the Company on April 29, 2024 Exhibit 99.5 Dear Valued Partner, I’m reaching out to share some exciting news about Deciphera – we have reached an agreement to be acquired by ONO Pharmaceutical, a global healthcare company dedicated to the fight against disease and pain. This combination marks the beginning of an exciting next chapter for Deciphera, one that we believe will advance our work to bring important medicines to more |
|
| April 29, 2024 |
Exhibit 99.3: Deciphera Email to certain investors of the Company on April 29, 2024 Exhibit 99.3 Subject: Deciphera Pharmaceuticals to be Acquired by ONO Pharmaceutical Good morning, I’m reaching out to make sure you saw the announcement that Deciphera has entered into a definitive agreement to be acquired by ONO Pharmaceutical, a global healthcare company grounded in a mission to fight against human disease and pain, and with a centuries-long track record of drug development. Un |
|
| April 29, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14D-9 SOLICITATION/RECOMMENDATION STATEMENT UNDER SECTION 14(d)(4) OF THE SECURITIES EXCHANGE ACT OF 1934 Deciphera Pharmaceuticals, Inc. (Name of Subject Company) Deciphera Pharmaceuticals, Inc. (Name of Persons Filing Statement) COMMON STOCK, PAR VALUE $0.01 PER SHARE (Title of Class of Securities) 24344T101 (CUSIP |
|
| April 29, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of Earliest Event Reported): April 29, 2024 Deciphera Pharmaceuticals, Inc. (Exact name of registrant as specified in its charter) Delaware 001-38219 30-1003521 (State or other jurisdiction of incorporation) (Com |
|
| April 29, 2024 |
Exhibit 99.1 Dear Colleagues, Moments ago, we announced an agreement under which ONO Pharmaceutical will acquire Deciphera Pharmaceuticals for $2.4 billion, or $25.60 per share, in cash. The full press release we issued is attached. For the past 20 years, Deciphera has worked toward one mission, inspired by patients: to defeat cancer. As a team, we have made incredible progress on this journey – g |
|
| April 29, 2024 |
Exhibit 99.1 Deciphera Pharmaceuticals to be Acquired by ONO Pharmaceutical For $2.4 Billion Deciphera Shareholders to Receive $25.60 per Share in Cash Deciphera’s Kinase Inhibitor Expertise and Established Commercialization Platform in Key Markets Will Reinforce ONO Pharmaceutical’s Pipeline and Accelerate Global Reach WALTHAM, Mass.—(BUSINESS WIRE)—April 29, 2024—Deciphera Pharmaceuticals, Inc. |
|
| April 29, 2024 |
Exhibit 99.2: Deciphera Employee FAQ, first used on April 29, 2024 Exhibit 99.2 Employee FAQ 1. What was announced? • Deciphera has agreed to be acquired by ONO Pharmaceutical—a global healthcare company whose purpose is to fight against human disease and pain with focus areas in oncology, immunology, neurology and specialty – for $2.4 billion, or $25.60 per share in cash. • Together, ONO and Deciphera will accelerate our shared vision to deliver innovative new d |
|
| April 25, 2024 |
Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) Filed by the Registrant ☒ Filed by a Party other than the Registrant ☐ Check the appropriate box: ☐ Preliminary Proxy Statement ☐ Confidential, for Use of the Commission Only (as permitted by Rule 14 |
|
| April 25, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) Filed by the Registrant ☒ Filed by a Party other than the Registrant ☐ Check the appropriate box: ☐ Preliminary Proxy Statement ☐ Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) ☐ Defin |
|
| April 22, 2024 |
Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. 1) Filed by the Registrant ☒ Filed by a Party other than the Registrant ☐ Check the appropriate box: ☒ Preliminary Proxy Statement ☐ Confidential, for Use of the Commission Only (as permitted by Rule 1 |
|
| April 11, 2024 |
Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) Filed by the Registrant ☒ Filed by a Party other than the Registrant ☐ Check the appropriate box: ☒ Preliminary Proxy Statement ☐ Confidential, for Use of the Commission Only (as permitted by Rule 14 |
|
| February 14, 2024 |
DCPH / Deciphera Pharmaceuticals, Inc. / BRAIDWELL LP - SC 13G/A Passive Investment SC 13G/A 1 ef20021616sc13ga.htm SC 13G/A UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. 1)* DECIPHERA PHARMACEUTICALS, INC. (Name of Issuer) Common Stock, $0.01 par value (Title of Class of Securities) 24344T101 (CUSIP Number) December 31, 2023 (Date of Event which Requires Filing of this Statement) Chec |
|
| February 14, 2024 |
DCPH / Deciphera Pharmaceuticals, Inc. / ARMISTICE CAPITAL, LLC Passive Investment SC 13G/A 1 armistice-dcph123123a2.htm UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 SCHEDULE 13G/A Under the Securities Exchange Act of 1934 (Amendment No. 2)* DECIPHERA PHARMACEUTICALS, INC. (Name of Issuer) Common Stock, $0.01 Par Value Per Share (Title of Class of Securities) 24344T101 (CUSIP Number) December 31, 2023 (Date of Event Which Requires Filing of this Statemen |
|
| February 14, 2024 |
EX-99.1 2 tm245846d21ex99-1.htm EXHIBIT 99.1 Exhibit 99.1 Joint Filing Agreement In accordance with Rule 13d-1(k)(1) under the Securities Exchange Act of 1934, as amended (the “Exchange Act”), the undersigned hereby agree to the joint filing on behalf of each of them of a Statement on Schedule 13G (including any and all amendments thereto, the “Schedule 13G”) relating to the Common Stock, $0.01 pa |
|
| February 14, 2024 |
DCPH / Deciphera Pharmaceuticals, Inc. / Redmile Group, LLC - SC 13G/A Passive Investment UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. 2) Deciphera Pharmaceuticals, Inc. (Name of Issuer) Common Stock, $0.01 par value (Title of Class of Securities) 24344T101 (CUSIP Number) December 31, 2023 (Date of Event Which Requires Filing of this Statement) Check the appropriate box to designate the rul |
|
| February 13, 2024 |
DCPH / Deciphera Pharmaceuticals, Inc. / VANGUARD GROUP INC - SCHEDULE 13G/A Passive Investment SC 13G/A 1 tv0737-decipherapharmaceutic.htm SCHEDULE 13G/A SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Schedule 13G Under the Securities Exchange Act of 1934 (Amendment No.: 3)* Name of issuer: Deciphera Pharmaceuticals Inc Title of Class of Securities: Common Stock CUSIP Number: 24344T101 Date of Event Which Requires Filing of this Statement: December 29, 2023 Check the appropriate |
|
| February 12, 2024 |
DCPH / Deciphera Pharmaceuticals, Inc. / Flynn James E Passive Investment SC 13G/A 1 e619254sc13ga-dp.htm SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 SCHEDULE 13G (Rule 13d-102) INFORMATION TO BE INCLUDED IN STATEMENTS FILED PURSUANT TO RULES 13d-1(b)(c), AND (d) AND AMENDMENTS THERETO FILED PURSUANT TO RULE 13d-2(b) (Amendment No. 1) * Deciphera Pharmaceuticals, Inc. (Name of Issuer) Common Stock, par value $0.01 per share (Title of Class of Securities) 243 |
|
| February 9, 2024 |
DCPH / Deciphera Pharmaceuticals, Inc. / Brightstar Associates Llc Passive Investment SC 13G/A 1 formsc13ga.htm UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. 2)* Deciphera Pharmaceuticals, Inc. (Name of Issuer) Common Stock (Title of Class of Securities) 24344T101 (CUSIP Number) December 31, 2023 (Date of Event which Requires filing of this Statement) Check the appropriate box to designa |
|
| February 7, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K (Mark One) ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2023 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number: 001-38 |
|
| February 7, 2024 |
DECIPHERA PHARMACUETICALS, INC. COMPENSATION RECOVERY POLICY Adopted as of September 28, 2023 Exhibit 10.30 DECIPHERA PHARMACUETICALS, INC. COMPENSATION RECOVERY POLICY Adopted as of September 28, 2023 Deciphera Pharmaceuticals, Inc., a Delaware corporation (the “Company”), has adopted a Compensation Recovery Policy (this “Policy”) as described below. 1. Overview The Policy sets forth the circumstances and procedures under which the Company shall recover Erroneously Awarded Compensation fr |
|
| February 7, 2024 |
Employment Agreement, between Deciphera Pharmaceuticals, LLC and Exhibit 10.31 EMPLOYMENT AGREEMENT This Employment Agreement (the “Agreement”) is made by and between Dashyant Dhanak (the “Executive”) and Deciphera Pharmaceuticals, LLC, a Delaware limited liability company (the “Company”). The Executive and the Company are collectively referred to as the “Parties”. This Agreement supersedes, amends and restates in all respects all prior discussions and agreemen |
|
| February 7, 2024 |
2022 Inducement Plan, as amended Exhibit 10.9 DECIPHERA PHARMACEUTICALS, INC. 2022 INDUCEMENT PLAN SECTION 1. GENERAL PURPOSE OF THE PLAN; DEFINITIONS The name of the plan is the Deciphera Pharmaceuticals, Inc. 2022 Inducement Plan (as amended, the “Plan”). The purpose of the Plan is to enable. (the “Company”) to grant equity awards to induce highly qualified prospective employees to accept employment and provide them with a prop |
|
| February 7, 2024 |
As filed with the Securities and Exchange Commission on February 7, 2024 As filed with the Securities and Exchange Commission on February 7, 2024 Registration No. |
|
| February 7, 2024 |
List of Subsidiaries of Registrant. Exhibit 21 DECIPHERA PHARMACEUTICALS, INC. The following is a list of significant subsidiaries of Deciphera Pharmaceuticals, Inc. as of December 31, 2023. SUBSIDIARY STATE OR OTHER JURISDICTION OF INCORPORATION OR ORGANIZATION Deciphera Pharmaceuticals, LLC Delaware Deciphera Pharmaceuticals Securities Corporation Massachusetts |
|
| February 7, 2024 |
Exhibit 107 Calculation of Filing Fee Tables Form S-8 (Form Type) Deciphera Pharmaceuticals, Inc. |
|
| February 6, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of Earliest Event Reported): February 6, 2024 Deciphera Pharmaceuticals, Inc. (Exact name of registrant as specified in its charter) Delaware 001-38219 30-1003521 (State or other jurisdiction of incorporation) (C |
|
| February 6, 2024 |
Exhibit 99.1 Deciphera Pharmaceuticals Announces Fourth Quarter and Full Year 2023 Financial Results – Fourth Quarter 2023 Total Revenue of $48.3 Million and Full Year 2023 Revenue of $163.4 Million; QINLOCK® Net Product Revenue Increased 27% to $159.1 Million in 2023 Compared to 2022 – – Expects to Submit NDA for Vimseltinib in the Second Quarter of 2024 and MAA in the Third Quarter of 2024 in Te |
|
| January 8, 2024 |
Exhibit 99.1 Deciphera Pharmaceuticals Announces Planned 2024 Corporate Milestones Supporting Evolution to a Self-Sustaining, Multi-Product Company – Preliminary Unaudited Fourth Quarter 2023 QINLOCK® Net Product Revenue of Approximately $46.0 Million, an Increase of 40% Compared to the Fourth Quarter of 2022 – – Expects to Submit Vimseltinib New Drug Application (NDA) in the Second Quarter of 202 |
|
| January 8, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of Earliest Event Reported): January 8, 2024 Deciphera Pharmaceuticals, Inc. (Exact name of registrant as specified in its charter) Delaware 001-38219 30-1003521 (State or other jurisdiction of incorporation) (Co |
|
| December 22, 2023 |
December 22, 2023 By EDGAR Submission U.S. Securities and Exchange Commission Division of Corporation Finance Office of Life Sciences 100 F Street, N.E. Washington, D.C. 20549 Attn: Christine Torney, Vanessa Robertson Re: Deciphera Pharmaceuticals, Inc. Form 10-K for the Year Ended December 31, 2022 Filed February 7, 2023 File No. 001-38219 Dear Ladies and Gentlemen: Deciphera Pharmaceuticals, Inc |
|
| October 30, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2023 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file numbe |
|
| October 30, 2023 |
Exhibit 99.1 Deciphera Pharmaceuticals Announces Third Quarter 2023 Financial Results – Third Quarter 2023 Total Revenue of $43.3 Million; Net Product Revenue for QINLOCK® (ripretinib) Increased 29% to $41.8 Million Compared to Third Quarter 2022 – – Announced Positive Top-line Results for MOTION Pivotal Phase 3 Study of Vimseltinib for TGCT and Updated Results from Phase 1/2 Study; NDA Submission |
|
| October 30, 2023 |
etween Deciphera Pharmaceuticals, LLC and Daniel L. Flynn Exhibit 10.1 August 1, 2023 BY DOCUSIGN Daniel L. Flynn, Ph.D. Re: Transition Agreement Dear Dan: I am writing to confirm arrangements with you concerning your retirement from employment with Deciphera Pharmaceuticals, LLC (the “Company”) and your anticipated continued engagement with the Company as a consultant after your retirement. The Company is deeply indebted to you for founding the Company |
|
| October 30, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of Earliest Event Reported): October 30, 2023 Deciphera Pharmaceuticals, Inc. (Exact name of registrant as specified in its charter) Delaware 001-38219 30-1003521 (State or other jurisdiction of incorporation) (C |
|
| October 30, 2023 |
Exhibit 10.2 CONSULTING AGREEMENT THIS CONSULTING AGREEMENT (together with the attached Business Terms Exhibit, the “Agreement”), is made as of January 1, 2024 (the “Effective Date”) by and between Deciphera Pharmaceuticals, LLC, a Delaware limited liability company with a principal business address at 200 Smith Street, Waltham, MA 02451 (“Deciphera”), and Daniel L. Flynn (“Consultant”). Deciphera |
|
| August 9, 2023 |
Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of Earliest Event Reported): August 9, 2023 Deciphera Pharmaceuticals, Inc. (Exact name of registrant as specified in its charter) Delaware 001-38219 30-1003521 (State or other jurisdiction of incorporation) (Com |
|
| August 9, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2023 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number: 00 |
|
| August 9, 2023 |
, dated May 3, 2023, by and between Deciphera Pharmaceuticals, LLC and Jefferies LLC Exhibit 10.1 OPEN MARKET SALE AGREEMENTSM May 3, 2023 JEFFERIES LLC 520 Madison Avenue New York, New York 10022 Ladies and Gentlemen: Deciphera Pharmaceuticals, Inc., a Delaware corporation (the “Company”), proposes, subject to the terms and conditions stated herein, to issue and sell from time to time through Jefferies LLC, as sales agent and/or principal (the “Agent”), shares of the Company’s co |
|
| August 9, 2023 |
EX-99.1 Exhibit 99.1 Deciphera Pharmaceuticals Announces Second Quarter 2023 Financial Results – Second Quarter 2023 Total Revenue of $38.3 Million; Net Product Revenue for QINLOCK® (ripretinib) Increased 18% to $37.3 Million Compared to Second Quarter 2022 – – Top-line Results for MOTION Pivotal Phase 3 Study of Vimseltinib Expected in Fourth Quarter 2023 – – INSIGHT Pivotal Phase 3 Study of QINL |
|
| August 3, 2023 |
EX-99.1 Exhibit 99.1 Deciphera Pharmaceuticals Announces Retirement of Daniel L. Flynn, Ph.D., and Appointment of Dashyant Dhanak, Ph.D., as Executive Vice President and Chief Scientific Officer — Director Ron Squarer Appointed Chairperson of the Board; James A. Bristol, Ph.D., continues as Board Member — WALTHAM, Mass.—(BUSINESS WIRE)—August 3, 2023— Deciphera Pharmaceuticals, Inc. (NASDAQ: DCPH) |
|
| August 3, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of Earliest Event Reported): August 1, 2023 Deciphera Pharmaceuticals, Inc. (Exact name of registrant as specified in its charter) Delaware 001-38219 30-1003521 (State or other jurisdiction of incorporation) (Com |
|
| June 22, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of Earliest Event Reported): June 21, 2023 Deciphera Pharmaceuticals, Inc. (Exact name of registrant as specified in its charter) Delaware 001-38219 30-1003521 (State or other jurisdiction of incorporation) (Comm |
|
| May 3, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of Earliest Event Reported): May 3, 2023 Deciphera Pharmaceuticals, Inc. (Exact name of registrant as specified in its charter) Delaware 001-38219 30-1003521 (State or other jurisdiction of incorporation) (Commis |
|
| May 3, 2023 |
Exhibit 107 Calculation of Filing Fee Tables Form S-3 (Form Type) Deciphera Pharmaceuticals, Inc. |
|
| May 3, 2023 |
EX-99.1 Exhibit 99.1 Deciphera Pharmaceuticals Announces First Quarter 2023 Financial Results – First Quarter 2023 Total Revenue of $33.4 Million; Net Product Revenue for QINLOCK® Increased 15% to $33.2 Million Compared to First Quarter 2022 – – Enrollment Complete in the MOTION Pivotal Phase 3 Study of Vimseltinib; Top-line Results Expected in the Fourth Quarter of 2023 – – QINLOCK Granted FDA Br |
|
| May 3, 2023 |
Exhibit 10.1 FORM OF PERFORMANCE-BASED RESTRICTED STOCK UNIT AWARD AGREEMENT FOR COMPANY EMPLOYEES UNDER Deciphera Pharmaceuticals, Inc. 2017 STOCK OPTION AND INCENTIVE PLAN Name of Grantee: No. of Performance-Based Restricted Stock Units: Grant Date: Pursuant to the Deciphera Pharmaceuticals, Inc. 2017 Stock Option and Incentive Plan as amended through the date hereof (the “Plan”), Deciphera Phar |
|
| May 3, 2023 |
EX-4.5 Exhibit 4.5 DECIPHERA PHARMACEUTICALS, INC. Issuer AND [TRUSTEE], Trustee INDENTURE Dated as of [ ] Subordinated Debt Securities TABLE OF CONTENTS1 Page Article 1 DEFINITIONS 1 Section 1.01 Definitions of Terms 1 Article 2 ISSUE, DESCRIPTION, TERMS, EXECUTION, REGISTRATION AND EXCHANGE OF SECURITIES 4 Section 2.01 Designation and Terms of Securities 4 Section 2.02 Form of Securities and Tru |
|
| May 3, 2023 |
Form of indenture for senior debt securities and the related form of senior debt security. EX-4.4 Exhibit 4.4 DECIPHERA PHARMACEUTICALS, INC. Issuer AND [TRUSTEE], Trustee INDENTURE Dated as of [ ] Senior Debt Securities TABLE OF CONTENTS1 Page Article 1 DEFINITIONS 1 Section 1.01 Definitions of Terms 1 Article 2 ISSUE, DESCRIPTION, TERMS, EXECUTION, REGISTRATION AND EXCHANGE OF SECURITIES 4 Section 2.01 Designation and Terms of Securities 4 Section 2.02 Form of Securities and Trustee’s |
|
| May 3, 2023 |
Exhibit 1.2 OPEN MARKET SALE AGREEMENTSM May 3, 2023 JEFFERIES LLC 520 Madison Avenue New York, New York 10022 Ladies and Gentlemen: Deciphera Pharmaceuticals, Inc., a Delaware corporation (the “Company”), proposes, subject to the terms and conditions stated herein, to issue and sell from time to time through Jefferies LLC, as sales agent and/or principal (the “Agent”), shares of the Company’s com |
|
| May 3, 2023 |
Exhibit 10.2 FORM OF PERFORMANCE-BASED RESTRICTED STOCK UNIT AWARD AGREEMENT FOR NON-U.S. GRANTEES UNDER DECIPHERA PHARMACEUTICALS, INC. 2017 STOCK OPTION AND INCENTIVE PLAN Name of Grantee: No. of Performance-Based Restricted Stock Units: Grant Date: Pursuant to the Deciphera Pharmaceuticals, Inc. 2017 Stock Option and Incentive Plan as amended through the date hereof (the “Plan”), Deciphera Phar |
|
| May 3, 2023 |
As filed with the Securities and Exchange Commission on May 3, 2023 S-3ASR Table of Contents As filed with the Securities and Exchange Commission on May 3, 2023 Registration No. |
|
| May 3, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2023 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number: 0 |
|
| April 26, 2023 |
Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) Filed by the Registrant ☒ Filed by a Party other than the Registrant ☐ Check the appropriate box: ☐ Preliminary Proxy Statement ☐ Confidential, for Use of the Commission Only (as permitted by Rule 14 |
|
| April 26, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) Filed by the Registrant ☒ Filed by a Party other than the Registrant ☐ Check the appropriate box: ☐ Preliminary Proxy Statement ☐ Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) ☐ Defin |
|
| March 22, 2023 |
DCPH / Deciphera Pharmaceuticals Inc / Flynn James E Passive Investment SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 SCHEDULE 13G (Rule 13d-102) INFORMATION TO BE INCLUDED IN STATEMENTS FILED PURSUANT TO RULES 13d-1(b)(c), AND (d) AND AMENDMENTS THERETO FILED PURSUANT TO RULE 13d-2(b) (Amendment No. |
|
| February 14, 2023 |
BANK OF AMERICA CORPORATION LIMITED POWER OF ATTORNEY BANK OF AMERICA CORPORATION BANK OF AMERICA CORPORATION LIMITED POWER OF ATTORNEY BANK OF AMERICA CORPORATION, a Delaware corporation (the "Corporation"), does hereby make, constitute, and appoint each of Kelvin Kwok, Tolu Tade, Andres Ortiz Custodio, Frank Lui, James Todd, Zainab Tarteel, Hannah Chae and Monica Yako as an attorney-in-fact for the Corporation acting for the Corporation and in the Corporation's name, place and stead, for the Corporation's use and benefit, to bind the Corporation by their execution of those agreements, forms and documents related specifically to Section 13 and Section 16 of the Securities Exchange Act of 1934, and other large shareholder and short position regulatory reporting requirements in other jurisdictions. |
|
| February 14, 2023 |
DCPH / Deciphera Pharmaceuticals Inc / BANK OF AMERICA CORP /DE/ Passive Investment UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G/A Under the Securities Exchange Act of 1934 (Amendment No. 01)* Deciphera Pharmaceuticals, Inc. (Name of Issuer) Common Stock (Title of Class of Securities) 24344T101 (CUSIP Number) December 31, 2022 (Date of Event Which Requires Filing of this Statement) Check the appropriate box to designate the rule pursuant to |
|
| February 14, 2023 |
DCPH / Deciphera Pharmaceuticals Inc / BRAIDWELL LP - SC 13G Passive Investment SC 13G 1 ny20007512x1sc13g.htm SC 13G UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. )* DECIPHERA PHARMACEUTICALS INC (Name of Issuer) Common Stock, $0.01 par value (Title of Class of Securities) 24344T101 (CUSIP Number) December 31, 2022 (Date of Event which Requires Filing of this Statement) Check the |
|
| February 14, 2023 |
EX-99.1 2 tm236041d5ex99-1.htm EXHIBIT 99.1 Exhibit 99.1 Joint Filing Agreement In accordance with Rule 13d-1(k)(1) under the Securities Exchange Act of 1934, as amended (the “Exchange Act”), the undersigned hereby agree to the joint filing on behalf of each of them of a Statement on Schedule 13G (including any and all amendments thereto, the “Schedule 13G”) relating to the Common Stock, $0.01 par |
|
| February 14, 2023 |
DCPH / Deciphera Pharmaceuticals Inc / Redmile Group, LLC - SC 13G/A Passive Investment SC 13G/A 1 tm236041d5sc13ga.htm SC 13G/A UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. 1) Deciphera Pharmaceuticals, Inc. (Name of Issuer) Common Stock, $0.01 par value (Title of Class of Securities) 24344T101 (CUSIP Number) December 31, 2022 (Date of Event Which Requires Filing of this Statement) Check |
|
| February 14, 2023 |
DCPH / Deciphera Pharmaceuticals Inc / ARMISTICE CAPITAL, LLC Passive Investment UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 SCHEDULE 13G/A Under the Securities Exchange Act of 1934 (Amendment No. |
|
| February 10, 2023 |
DCPH / Deciphera Pharmaceuticals Inc / Flynn James E Passive Investment SC 13G/A 1 e618239sc13ga-deciphera.htm SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 SCHEDULE 13G (Rule 13d-102) INFORMATION TO BE INCLUDED IN STATEMENTS FILED PURSUANT TO RULES 13d-1(b)(c), AND (d) AND AMENDMENTS THERETO FILED PURSUANT TO RULE 13d-2(b) (Amendment No. 2) * Deciphera Pharmaceuticals, Inc. (Name of Issuer) Common Stock, par value $0.01 per share (Title of Class of Securiti |
|
| February 9, 2023 |
DCPH / Deciphera Pharmaceuticals Inc / VANGUARD GROUP INC - SCHEDULE 13G/A Passive Investment SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Schedule 13G Under the Securities Exchange Act of 1934 (Amendment No.: 2)* Name of issuer: Deciphera Pharmaceuticals Inc. Title of Class of Securities: Common Stock CUSIP Number: 24344T101 Date of Event Which Requires Filing of this Statement: December 30, 2022 Check the appropriate box to designate the rule pursuant to which this Schedule |
|
| February 8, 2023 |
DCPH / Deciphera Pharmaceuticals Inc / Brightstar Associates Llc - SC 13G/A Passive Investment SC 13G/A 1 d448752dsc13ga.htm SC 13G/A UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. 1)* Deciphera Pharmaceuticals, Inc. (Name of Issuer) Common Stock (Title of Class of Securities) 24344T101 (CUSIP Number) December 31, 2022 (Date of Event which Requires filing of this Statement) Check the appropriate b |
|
| February 7, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of Earliest Event Reported): February 7, 2023 Deciphera Pharmaceuticals, Inc. (Exact name of registrant as specified in its charter) Delaware 001-38219 30-1003521 (State or other jurisdiction of incorporation) (C |
|
| February 7, 2023 |
EX-FILING FEES Exhibit 107 Calculation of Filing Fee Tables Form S-8 (Form Type) Deciphera Pharmaceuticals, Inc. |
|
| February 7, 2023 |
As filed with the Securities and Exchange Commission on February 7, 2023 S-8 As filed with the Securities and Exchange Commission on February 7, 2023 Registration No. |
|
| February 7, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K (Mark One) ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2022 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number: 001-38 |
|
| February 7, 2023 |
Deciphera Pharmaceuticals, Inc. Amended and Restated Non-Employee Director Compensation Policy. Exhibit 10.21 Deciphera Pharmaceuticals, Inc. Amended and Restated Non-Employee Director Compensation Policy The purpose of this Amended and Restated Non-Employee Director Compensation Policy (this “Policy”) of Deciphera Pharmaceuticals, Inc., a Delaware corporation (the “Company”), is to provide a total compensation package that enables the Company to attract and retain, on a long-term basis, hig |
|
| February 7, 2023 |
2022 Inducement Plan, as amended Exhibit 10.9 DECIPHERA PHARMACEUTICALS, INC. 2022 INDUCEMENT PLAN SECTION 1. GENERAL PURPOSE OF THE PLAN; DEFINITIONS The name of the plan is the Deciphera Pharmaceuticals, Inc. 2022 Inducement Plan (as amended, the “Plan”). The purpose of the Plan is to enable. (the “Company”) to grant equity awards to induce highly qualified prospective employees to accept employment and provide them with a prop |
|
| February 7, 2023 |
Exhibit 99.1 Deciphera Pharmaceuticals Announces Fourth Quarter and Full Year 2022 Financial Results – Fourth Quarter 2022 Total Revenue of $36.3 Million and Full Year 2022 Revenue of $134.0 Million; QINLOCK® Net Product Revenue Increased 44% to $125.5 Million in 2022 Compared to 2021 – – Expects to Complete Enrollment in the MOTION Pivotal Phase 3 Study of Vimseltinib in the First Quarter of 2023 |
|
| February 7, 2023 |
List of Subsidiaries of Registrant. Exhibit 21 DECIPHERA PHARMACEUTICALS, INC. The following is a list of significant subsidiaries of Deciphera Pharmaceuticals, Inc. as of December 31, 2022. SUBSIDIARY STATE OR OTHER JURISDICTION OF INCORPORATION OR ORGANIZATION Deciphera Pharmaceuticals, LLC Delaware Deciphera Pharmaceuticals Securities Corporation Massachusetts |
|
| January 20, 2023 |
Entry into a Material Definitive Agreement, Financial Statements and Exhibits UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of Earliest Event Reported): January 20, 2023 (January 19, 2023) Deciphera Pharmaceuticals, Inc. (Exact name of registrant as specified in its charter) Delaware 001-38219 30-1003521 (State or other jurisdiction o |
|
| January 20, 2023 |
Underwriting Agreement dated January 19, 2023 Exhibit 1.1 DECIPHERA PHARMACEUTICALS, INC. 6,944,445 shares of common stock, par value $0.01 per share Underwriting Agreement January 19, 2023 J.P. Morgan Securities LLC Jefferies LLC Cowen and Company, LLC Guggenheim Securities, LLC As Representatives of the several Underwriters listed in Schedule 1 hereto c/o J.P. Morgan Securities LLC 383 Madison Avenue New York, New York 10179 c/o Jefferies L |
|
| January 20, 2023 |
Prospectus supplement dated January 19, 2023 424B5 1 d358838d424b5.htm 424B5 Table of Contents Filed Pursuant to Rule 424(b)(5) Registration No. 333-266523 Prospectus supplement (To prospectus dated August 10, 2022) 6,944,445 shares Common stock We are offering 6,944,445 shares of our common stock with an aggegate offering price of approximately $125 million pursuant to this prospectus supplement and the accompanying prospectus. Our common s |
|
| January 18, 2023 |
Prospectus supplement dated , 2023 Table of Contents Filed Pursuant to Rule 424(b)(5) Registration No. 333-266523 The information in this preliminary prospectus supplement is not complete and may be changed. A registration statement relating to these securities has been filed with the Securities and Exchange Commission and is effective. This preliminary prospectus supplement and the accompanying prospectus are not an offer to sell |
|
| January 18, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of Earliest Event Reported): January 18, 2023 Deciphera Pharmaceuticals, Inc. (Exact name of registrant as specified in its charter) Delaware 001-38219 30-1003521 (State or other jurisdiction of incorporation) (C |
|
| January 3, 2023 |
EX-99.2 Exhibit 99.2 Deciphera Pharmaceuticals Announces Results from ctDNA Analysis from INTRIGUE Phase 3 Clinical Study Demonstrating Substantial Clinical Benefit of QINLOCK® in Second-Line GIST Patients with Mutations in KIT Exon 11 and 17/18 Only – Median Progression Free Survival for QINLOCK of 14.2 Months Versus Sunitinib of 1.5 Months; Hazard Ratio of 0.22, nominal p value <0.0001 – – Objec |
|
| January 3, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of Earliest Event Reported): January 3, 2023 Deciphera Pharmaceuticals, Inc. (Exact name of registrant as specified in its charter) Delaware 001-38219 30-1003521 (State or other jurisdiction of incorporation) (Co |
|
| January 3, 2023 |
EX-99.1 Exhibit 99.1 Deciphera Pharmaceuticals Announces Planned 2023 Corporate Milestones to Support Continued Evolution to Multi-Product Company – Plans to Initiate Pivotal Phase 3 INSIGHT Study of QINLOCK® Versus Sunitinib in Second-Line GIST Patients with Mutations in KIT Exon 11 and 17/18 Only in the Second Half of 2023 Based on ctDNA Analysis from INTRIGUE Study – – Expects to Complete Enrol |
|
| November 3, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ? QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2022 OR ? TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file numbe |
|
| November 3, 2022 |
Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of Earliest Event Reported): November 3, 2022 Deciphera Pharmaceuticals, Inc. (Exact name of registrant as specified in its charter) Delaware 001-38219 30-1003521 (State or other jurisdiction of incorporation) (C |
|
| November 3, 2022 |
EX-99.1 2 d408583dex991.htm EX-99.1 Exhibit 99.1 Deciphera Pharmaceuticals, Inc. Announces Third Quarter 2022 Financial Results – Third Quarter 2022 Total Revenue of $36.0 Million; QINLOCK® Net Product Revenue Increases 49% to $32.3 Million Compared to Third Quarter 2021 – – Presented Updated Results from Phase 1/2 Study of Vimseltinib in TGCT Patients at the ESMO Congress 2022 Demonstrating Best- |
|
| September 12, 2022 |
EX-99.2 Exhibit 99.2 Deciphera Pharmaceuticals, Inc. Presents Updated Phase 1/2 Data for Vimseltinib in TGCT at the European Society for Medical Oncology (ESMO) Congress 2022 – Updated Results for Vimseltinib Showed Objective Response Rate of 69% in Phase 1, 53% in Phase 2 Cohort A, and 46% in Phase 2 Cohort B; Demonstrated a Clinical Benefit Rate of 100% Across All Phase 1/2 Patients – – Prelimin |
|
| September 12, 2022 |
EX-99.1 Exhibit 99.1 Deciphera Pharmaceuticals, Inc. Presents Initial Phase 1 Single Agent Dose Escalation Data for First-in- Class ULK Inhibitor of Autophagy, DCC-3116, at the European Society for Medical Oncology (ESMO) Congress 2022 – DCC-3116 Was Well-tolerated with No Dose Limiting Toxicities or Treatment-Related Serious Adverse Events Observed – – Pharmacokinetic and Pharmacodynamic Data Acr |
|
| September 12, 2022 |
Regulation FD Disclosure, Financial Statements and Exhibits UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of Earliest Event Reported): September 10, 2022 Deciphera Pharmaceuticals, Inc. (Exact name of registrant as specified in its charter) Delaware 001-38219 30-1003521 (State or other jurisdiction of incorporation) |
|
| August 8, 2022 |
VIA EDGAR August 8, 2022 United States Securities and Exchange Commission Division of Corporation Finance 100 F Street, N. |
|
| August 4, 2022 |
Exhibit 107 Calculation of Filing Fee Tables Form S-3 (Form Type) Deciphera Pharmaceuticals, Inc. |
|
| August 4, 2022 |
Form of indenture for senior debt securities and the related form of senior debt security. Exhibit 4.4 DECIPHERA PHARMACEUTICALS, INC. Issuer AND [TRUSTEE], Trustee INDENTURE Dated as of [ ] Senior Debt Securities TABLE OF CONTENTS1 Page Article 1 DEFINITIONS 1 Section 1.01 Definitions of Terms 1 Article 2 ISSUE, DESCRIPTION, TERMS, EXECUTION, REGISTRATION AND EXCHANGE OF SECURITIES 4 Section 2.01 Designation and Terms of Securities 4 Section 2.02 Form of Securities and Trustee?s Certif |
|
| August 4, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ? QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2022 OR ? TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number: 00 |
|
| August 4, 2022 |
Exhibit 99.1 Deciphera Pharmaceuticals, Inc. Announces Second Quarter 2022 Financial Results ? Second Quarter 2022 Total Revenue of $32.5 Million; QINLOCK? Net Product Revenue Increases 43% to $31.5 Million Compared to Second Quarter 2021 ? ? Phase 1 Single Agent Dose Escalation Data for DCC-3116 Selected for Oral Presentation as a Proffered Paper at the ESMO Congress 2022 in September ? ? Updated |
|
| August 4, 2022 |
Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of Earliest Event Reported): August 4, 2022 Deciphera Pharmaceuticals, Inc. (Exact name of registrant as specified in its charter) Delaware 001-38219 30-1003521 (State or other jurisdiction of incorporation) (Com |
|
| August 4, 2022 |
Exhibit 4.5 DECIPHERA PHARMACEUTICALS, INC. Issuer AND [TRUSTEE], Trustee INDENTURE Dated as of [ ] Subordinated Debt Securities TABLE OF CONTENTS1 Page Article 1 DEFINITIONS 1 Section 1.01 Definitions of Terms 1 Article 2 ISSUE, DESCRIPTION, TERMS, EXECUTION, REGISTRATION AND EXCHANGE OF SECURITIES 4 Section 2.01 Designation and Terms of Securities 4 Section 2.02 Form of Securities and Trustee?s |
|
| August 4, 2022 |
Exhibit 1.3 AMENDMENT NO. 1 TO THE OPEN MARKET SALE AGREEMENTSM August 4, 2022 JEFFERIES LLC 520 Madison Avenue New York, New York 10022 Ladies and Gentlemen: This Amendment No. 1 to the Open Market Sale AgreementSM (this ?Amendment?) is entered into as of the date first written above by Deciphera Pharmaceuticals, Inc., a Delaware corporation (the ?Company?), and Jefferies LLC (?Agent?), that are |
|
| August 4, 2022 |
As filed with the Securities and Exchange Commission on August 4, 2022 Table of Contents As filed with the Securities and Exchange Commission on August 4, 2022 Registration No. |
|
| June 24, 2022 |
Submission of Matters to a Vote of Security Holders UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of Earliest Event Reported): June 23, 2022 Deciphera Pharmaceuticals, Inc. (Exact name of registrant as specified in its charter) Delaware 001-38219 30-1003521 (State or other jurisdiction of incorporation) (Comm |
|
| May 9, 2022 |
DCPH / Deciphera Pharmaceuticals Inc / Redmile Group, LLC - SC 13G Passive Investment UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. ) Deciphera Pharmaceuticals, Inc. (Name of Issuer) Common Stock, $0.01 par value (Title of Class of Securities) 24344T101 (CUSIP Number) April 29, 2022 (Date of Event Which Requires Filing of this Statement) Check the appropriate box to designate the rule pu |
|
| May 9, 2022 |
Exhibit 99.1 Joint Filing Agreement In accordance with Rule 13d-1(k)(1) under the Securities Exchange Act of 1934, as amended (the ?Exchange Act?), the undersigned hereby agree to the joint filing on behalf of each of them of a Statement on Schedule 13G (including any and all amendments thereto, the ?Schedule 13G?) relating to the Common Stock, $0.01 par value per share, of Deciphera Pharmaceutica |
|
| May 4, 2022 |
Exhibit 99.1 Deciphera Pharmaceuticals, Inc. Announces First Quarter 2022 Financial Results ? First Quarter 2022 Revenue of $29.2 Million ? ? Net Proceeds of $163.4 Million from Public Offering in April, Enabling the Company to Fund Operating and Capital Expenditures into 2025 ? ? Pivotal Phase 3 MOTION Study of Vimseltinib in TGCT Patients Underway; Updated Phase 1/2 Results Expected in 2H 2022 ? |
|
| May 4, 2022 |
Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of Earliest Event Reported): May 4, 2022 Deciphera Pharmaceuticals, Inc. (Exact name of registrant as specified in its charter) Delaware 001-38219 30-1003521 (State or other jurisdiction of incorporation) (Commis |
|
| May 4, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2022 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number: 0 |
|
| April 28, 2022 |
Exhibit 4.1 DECIPHERA PHARMACEUTICALS, INC. FORM OF WARRANT TO PURCHASE COMMON STOCK Number of Shares: [?] (subject to adjustment) Warrant No. [?] Original Issue Date: [], 2022 Deciphera Pharmaceuticals, Inc., a Delaware corporation (the ?Company?), hereby certifies that, for good and valuable consideration, the receipt and sufficiency of which are hereby acknowledged, [?] or its permitted registe |
|
| April 28, 2022 |
Entry into a Material Definitive Agreement, Financial Statements and Exhibits UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of Earliest Event Reported): April 26, 2022 Deciphera Pharmaceuticals, Inc. (Exact name of registrant as specified in its charter) Delaware 001-38219 30-1003521 (State or other jurisdiction of incorporation) (Com |
|
| April 28, 2022 |
Prospectus supplement dated April 26, 2022 Table of Contents Filed Pursuant to Rule 424(b)(5) Registration No. 333-236389 Prospectus supplement (To prospectus dated March 10, 2022) $150,000,000 Common stock Pre-funded warrants to purchase common stock We are offering shares of our common stock and, in lieu of common stock to certain investors, pre-funded warrants to purchase shares of our common stock with an aggregate offering price of $1 |
|
| April 28, 2022 |
Underwriting Agreement dated April 26, 2022 Exhibit 1.1 Execution Version DECIPHERA PHARMACEUTICALS, INC. 5,251,239 shares of common stock, par value $0.01 per share and pre-funded warrants to purchase 9,748,761 shares of common stock Underwriting Agreement April 26, 2022 J.P. Morgan Securities LLC Jefferies LLC As Representatives of the several Underwriters listed in Schedule 1 hereto c/o J.P. Morgan Securities LLC 383 Madison Avenue New Y |
|
| April 26, 2022 |
DEFA14A 1 dcphproxyadditionalmateria.htm DEFA14A UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) Filed by the Registrant ☒ Filed by a Party other than the Registrant ☐ Check the appropriate box: ☐ Preliminary Proxy Statement ☐ Confidential, for Use of the Commissio |
|
| April 26, 2022 |
Results of Operations and Financial Condition, Other Events UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of Earliest Event Reported): April 26, 2022 Deciphera Pharmaceuticals, Inc. (Exact name of registrant as specified in its charter) Delaware 001-38219 30-1003521 (State or other jurisdiction of incorporation) (Com |
|
| April 26, 2022 |
Prospectus supplement dated , 2022 Table of Contents Filed Pursuant to Rule 424(b)(5) Registration No. 333-236389 The information in this preliminary prospectus supplement is not complete and may be changed. A registration statement relating to these securities has been filed with the Securities and Exchange Commission and is effective. This preliminary prospectus supplement and the accompanying prospectus are not an offer to sell |
|
| April 26, 2022 |
Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) Filed by the Registrant ? Filed by a Party other than the Registrant ? Check the appropriate box: ? Preliminary Proxy Statement ? Confidential, for Use of the Commission Only (as permitted by Rule 14 |
|
| February 15, 2022 |
DCPH / Deciphera Pharmaceuticals Inc / ARMISTICE CAPITAL, LLC - SC 13G Passive Investment UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. |
|
| February 15, 2022 |
Exhibit 99.1 JOINT FILING AGREEMENT In accordance with Rule 13d-1(k)(1) under the Securities Exchange Act of 1934, as amended, the persons named below agree to the joint filing on behalf of each of them of a Statement on Schedule 13G (including additional amendments thereto) with respect to the shares of Common Stock, par value $0.01, of Deciphera Pharmaceuticals, Inc. This Joint Filing Agreement |
|
| February 14, 2022 |
DCPH / Deciphera Pharmaceuticals Inc / Redmile Group, LLC - SC 13G/A Passive Investment UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G/A Under the Securities Exchange Act of 1934 (Amendment No. 2) DECIPHERA PHARMACEUTICALS, INC. (Name of Issuer) Common Stock, $0.01 par value (Title of Class of Securities) 24344T101 (CUSIP Number) December 31, 2021 (Date of Event Which Requires Filing of this Statement) Check the appropriate box to designate the r |
|
| February 14, 2022 |
Exhibit 99.1 Joint Filing Agreement In accordance with Rule 13d-1(k)(1) under the Securities Exchange Act of 1934, as amended (the ?Exchange Act?), the undersigned hereby agree to the joint filing on behalf of each of them of a Statement on Schedule 13G (including any and all amendments thereto, the ?Schedule 13G?) relating to the Common Stock, $0.01 par value per share, of Deciphera Pharmaceutica |
|
| February 11, 2022 |
Exhibit 99.1 Deciphera Pharmaceuticals, Inc. EDITED TRANSCRIPT Q4 2021 & FY 2021 Earnings Call Event Date/Time: February 8, 2022 / 4:30 pm ET Operator Good afternoon, everyone, and welcome to the Deciphera Pharmaceuticals Fourth Quarter and Full Year 2021 Financial Results Conference Call. Today?s call is being recorded. At this time, I would like to turn the call over to Maghan Meyers, Senior Vic |
|
| February 11, 2022 |
Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of Earliest Event Reported): February 8, 2022 Deciphera Pharmaceuticals, Inc. (Exact name of registrant as specified in its charter) Delaware 001-38219 30-1003521 (State or other jurisdiction of incorporation) (C |
|
| February 11, 2022 |
DCPH / Deciphera Pharmaceuticals Inc / Flynn James E Passive Investment SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 SCHEDULE 13G (Rule 13d-102) INFORMATION TO BE INCLUDED IN STATEMENTS FILED PURSUANT TO RULES 13d-1(b)(c), AND (d) AND AMENDMENTS THERETO FILED PURSUANT TO RULE 13d-2(b) (Amendment No. |
|
| February 9, 2022 |
DCPH / Deciphera Pharmaceuticals Inc / VANGUARD GROUP INC - SCHEDULE 13G/A Passive Investment SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Schedule 13G Under the Securities Exchange Act of 1934 (Amendment No.: 1)* Name of issuer: Deciphera Pharmaceuticals Inc. Title of Class of Securities: Common Stock CUSIP Number: 24344T101 Date of Event Which Requires Filing of this Statement: December 31, 2021 Check the appropriate box to designate the rule pursuant to which this Schedule |
|
| February 9, 2022 |
As filed with the Securities and Exchange Commission on February 8, 2022 S-8 1 d306968ds8.htm S-8 As filed with the Securities and Exchange Commission on February 8, 2022 Registration No. 333- UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM S-8 REGISTRATION STATEMENT Under The Securities Act of 1933 DECIPHERA PHARMACEUTICALS, INC. (Exact name of registrant as specified in its charter) Delaware 30-1003521 (State or other jurisdiction of inco |
|
| February 9, 2022 |
Calculation of Filing Fee Tables Form S-8 (Form Type) Deciphera Pharmaceuticals, Inc. |
|
| February 8, 2022 |
Exhibit 10.11 RESTRICTED STOCK UNIT AWARD AGREEMENT FOR COMPANY EMPLOYEES UNDER DECIPHERA PHARMACEUTICALS, INC. 2022 INDUCEMENT PLAN Name of Grantee: No. of Restricted Stock Units: Grant Date: Pursuant to the Deciphera Pharmaceuticals, Inc. 2022 Inducement Plan as amended through the date hereof (the ?Plan?), Deciphera Pharmaceuticals, Inc. (the ?Company?) hereby grants an award of the number of R |
|
| February 8, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K (Mark One) ? ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2021 OR ? TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number: 001-38 |
|
| February 8, 2022 |
Exhibit 10.10 NON-QUALIFIED STOCK OPTION AGREEMENT FOR COMPANY EMPLOYEES UNDER DECIPHERA PHARMACEUTICALS, INC. 2022 INDUCEMENT PLAN Name of Optionee: No. of Option Shares: Option Exercise Price per Share: Grant Date: Expiration Date: Pursuant to the Deciphera Pharmaceuticals, Inc. 2022 Inducement Plan as amended through the date hereof (the ?Plan?), Deciphera Pharmaceuticals, Inc. (the ?Company?) |
|
| February 8, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of Earliest Event Reported): February 8, 2022 Deciphera Pharmaceuticals, Inc. (Exact name of registrant as specified in its charter) Delaware 001-38219 30-1003521 (State or other jurisdiction of incorporation) (C |
|
| February 8, 2022 |
Exhibit 107 Calculation of Filing Fee Tables Form S-3 (Form Type) Deciphera Pharmaceuticals, Inc. |
|
| February 8, 2022 |
Exhibit 10.9 DECIPHERA PHARMACEUTICALS, INC. 2022 INDUCEMENT PLAN SECTION 1. GENERAL PURPOSE OF THE PLAN; DEFINITIONS The name of the plan is the Deciphera Pharmaceuticals, Inc. 2022 Inducement Plan (the ?Plan?). The purpose of the Plan is to enable. (the ?Company?) to grant equity awards to induce highly qualified prospective employees to accept employment and provide them with a proprietary inte |
|
| February 8, 2022 |
As filed with the Securities and Exchange Commission on February 8, 2022 POS AM 1 d303247dposam.htm POS AM Table of Contents As filed with the Securities and Exchange Commission on February 8, 2022 Registration No. 333-236389 UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 POST-EFFECTIVE AMENDMENT NO. 2 TO FORM S-3 REGISTRATION STATEMENT UNDER THE SECURITIES ACT OF 1933 DECIPHERA PHARMACEUTICALS, INC. (Exact name of registrant as specified in its |
|
| February 8, 2022 |
As filed with the Securities and Exchange Commission on February 8, 2022 POSASR 1 d270841dposasr.htm POSASR Table of Contents As filed with the Securities and Exchange Commission on February 8, 2022 Registration No. 333-236389 UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 POST-EFFECTIVE AMENDMENT NO. 1 TO FORM S-3 REGISTRATION STATEMENT UNDER THE SECURITIES ACT OF 1933 DECIPHERA PHARMACEUTICALS, INC. (Exact name of registrant as specified in its |
|
| February 8, 2022 |
List of Subsidiaries of Registrant. Exhibit 21 DECIPHERA PHARMACEUTICALS, INC. The following is a list of significant subsidiaries of Deciphera Pharmaceuticals, Inc. as of December 31, 2021. SUBSIDIARY STATE OR OTHER JURISDICTION OF INCORPORATION OR ORGANIZATION Deciphera Pharmaceuticals, LLC Delaware Deciphera Pharmaceuticals Securities Corporation Massachusetts |
|
| February 8, 2022 |
Exhibit 99.1 Deciphera Pharmaceuticals, Inc. Announces Fourth Quarter and Full Year 2021 Financial Results ? Fourth Quarter 2021 Revenue of $24.2 Million and Full Year 2021 Revenue of $96.1 Million ? ? Launch of QINLOCK? in Europe Underway ? ? Pivotal Phase 3 MOTION Study of Vimseltinib in TGCT Patients Underway; Updated Phase 1/2 Data Expected in 2H 2022 ? ? Phase 1 Single Agent Dose Escalation D |
|
| February 3, 2022 |
DCPH / Deciphera Pharmaceuticals Inc / FRANKLIN RESOURCES INC Passive Investment CUSIP NO. 24344T101 13G Page 1 of 13 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. 1)* DECIPHERA PHARMACEUTICALS, INC. (Name of Issuer) Common Stock, $0.01 Par Value Per Share (Title of Class of Securities) 24344T101 (CUSIP Number) December 31, 2021 (Date of Event Which Requires Filing of this Statement |
|
| January 31, 2022 |
DCPH / Deciphera Pharmaceuticals Inc / BANK OF AMERICA CORP /DE/ Passive Investment UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. N/A)* Deciphera Pharmaceuticals, Inc. (Name of Issuer) Common Stock (Title of Class of Securities) 24344T101 (CUSIP Number) December 31, 2021 (Date of Event Which Requires Filing of this Statement) Check the appropriate box to designate the rule pursuant to |
|
| January 24, 2022 |
Exhibit 99.1 Deciphera Pharmaceuticals Presents Results from the INTRIGUE Phase 3 Clinical Study at the American Society of Clinical Oncology Plenary Series Session ? Efficacy Observed with QINLOCK? was Comparable to Sunitinib with a More Favorable Safety and Tolerability Profile in GIST Patients Previously Treated with Imatinib ? Waltham, MA ? January 24, 2022 ? Deciphera Pharmaceuticals, Inc. (N |
|
| January 24, 2022 |
Regulation FD Disclosure, Financial Statements and Exhibits UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of Earliest Event Reported): January 24, 2022 Deciphera Pharmaceuticals, Inc. (Exact name of registrant as specified in its charter) Delaware 001-38219 30-1003521 (State or other jurisdiction of incorporation) (C |
|
| January 10, 2022 |
EX-99.1 Exhibit 99.1 Deciphera Pharmaceuticals Provides Corporate Update and Highlights Key 2022 Corporate Milestones – Launch of QINLOCK® in Germany Underway; Transition to Post-approval Paid Access Program in France Expected in 1H 2022 – – Pivotal Phase 3 MOTION Study of Vimseltinib in TGCT Patients Underway; Updated Phase 1/2 Data Expected in 2H 2022 – – Phase 1 Dose Escalation Data for DCC-311 |
|
| January 10, 2022 |
Regulation FD Disclosure, Financial Statements and Exhibits UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of Earliest Event Reported): January 10, 2022 Deciphera Pharmaceuticals, Inc. (Exact name of registrant as specified in its charter) Delaware 001-38219 30-1003521 (State or other jurisdiction of incorporation) (C |
|
| November 30, 2021 |
Exhibit 99.1 Deciphera Pharmaceuticals Announces Restructuring to Prioritize Clinical Development Programs and Streamline Commercial Operations ? Resources Focused on the Clinical Development of Vimseltinib and DCC-3116; Rebastinib Program Discontinued ? ? US Commercial Operations Streamlined and Launches Planned in Select European Markets for QINLOCK? ? ? Workforce Reduction of Approximately 35% |
|
| November 30, 2021 |
Financial Statements and Exhibits, Costs Associated with Exit or Disposal Activities, Other Events UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of Earliest Event Reported): November 30, 2021 Deciphera Pharmaceuticals, Inc. (Exact name of registrant as specified in its charter) Delaware 001-38219 30-1003521 (State or other jurisdiction of incorporation) ( |
|
| November 22, 2021 |
Regulation FD Disclosure, Financial Statements and Exhibits, Other Events UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of Earliest Event Reported): November 19, 2021 Deciphera Pharmaceuticals, Inc. (Exact name of registrant as specified in its charter) Delaware 001-38219 30-1003521 (State or other jurisdiction of incorporation) ( |
|
| November 22, 2021 |
Exhibit 99.1 Deciphera Receives European Commission Approval of QINLOCK? for the Treatment of Fourth-Line Gastrointestinal Stromal Tumor ? QINLOCK Significantly Reduced the Risk of Disease Progression or Death by 85% and Showed Clinically Meaningful Overall Survival in the INVICTUS Phase 3 Study ? Waltham, MA ? November 22, 2021 ? Deciphera Pharmaceuticals, Inc. (NASDAQ: DCPH), a commercial-stage |
|
| November 10, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of Earliest Event Reported): November 10, 2021 Deciphera Pharmaceuticals, Inc. (Exact name of registrant as specified in its charter) Delaware 001-38219 30-1003521 (State or other jurisdiction of incorporation) ( |
|
| November 10, 2021 |
DCPH / Deciphera Pharmaceuticals Inc / Flynn James E Passive Investment SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 SCHEDULE 13G (Rule 13d-102) INFORMATION TO BE INCLUDED IN STATEMENTS FILED PURSUANT TO RULES 13d-1(b)(c), AND (d) AND AMENDMENTS THERETO FILED PURSUANT TO RULE 13d-2(b) (Amendment No. |
|
| November 5, 2021 |
Regulation FD Disclosure, Financial Statements and Exhibits, Other Events UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of Earliest Event Reported): November 5, 2021 Deciphera Pharmaceuticals, Inc. (Exact name of registrant as specified in its charter) Delaware 001-38219 30-1003521 (State or other jurisdiction of incorporation) (C |
|
| November 5, 2021 |
Exhibit 99.1 Deciphera Pharmaceuticals Announces Top-line Results from the INTRIGUE Phase 3 Clinical Study ? Study Did Not Achieve Primary Efficacy Endpoint of Improved Progression-Free Survival Versus Standard of Care Sunitinib in Patients with Second-line GIST ? ? Conference Call to be Held Today at 8:00 AM ET ? Waltham, MA ? November 5, 2021 ? Deciphera Pharmaceuticals, Inc. (NASDAQ: DCPH), a c |
|
| November 2, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ? QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2021 OR ? TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file numbe |
|
| November 2, 2021 |
Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of Earliest Event Reported): November 2, 2021 Deciphera Pharmaceuticals, Inc. (Exact name of registrant as specified in its charter) Delaware 001-38219 30-1003521 (State or other jurisdiction of incorporation) (C |
|
| November 2, 2021 |
Exhibit 99.1 Deciphera Pharmaceuticals, Inc. Announces Third Quarter 2021 Financial Results ? Third Quarter 2021 Revenue of $23.2 Million, Including QINLOCK? (ripretinib) Net Product Revenue of $21.7 Million ? ? Top-line Results from INTRIGUE Phase 3 Study of QINLOCK in Patients with Second-line Gastrointestinal Stromal Tumor (GIST) Expected in the Fourth Quarter of 2021 ? ? Approval from the Euro |
|
| November 2, 2021 |
November 2, 2021 By EDGAR Submission U.S. Securities and Exchange Commission Division of Corporation Finance Office of Life Sciences 100 F Street, N.E. Washington, D.C. 20549 Attn: Jenn Do, Angela Connell Re: Deciphera Pharmaceuticals, Inc. Form 10-K for the Fiscal Year Ended December 31, 2020 Filed February 9, 2021 File No. 001-38219 Dear Ladies and Gentlemen: Deciphera Pharmaceuticals, Inc. (“De |
|
| October 8, 2021 |
CERTAIN PORTIONS OF THIS LETTER AS FILED VIA EDGAR HAVE BEEN OMITTED AND FILED SEPARATELY WITH THE COMMISSION. |
|
| September 29, 2021 |
Submission of Matters to a Vote of Security Holders UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K/A (Amendment No. 1) CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of Earliest Event Reported): June 23, 2021 Deciphera Pharmaceuticals, Inc. (Exact name of registrant as specified in its charter) Delaware 001-38219 30-1003521 (State or other jurisdiction of |
|
| September 17, 2021 |
Exhibit 99.3 Safety and preliminary efficacy of vimseltinib in tenosynovial giant cell tumor (TGCT) Gelderblom H1, Abdul Razak AR2, S?nchez-Gastaldo A3, Rutkowski P4, Wilky BA5, Wagner AJ6, van de Sande M7, Michenzie M8, Vallee M8, Sharma M8, Sherman ML8, Ruiz-Soto R8, Tap WD9 1Medical Oncology, Leiden University Medical Center, Leiden, Netherlands; 2Toronto Sarcoma Program, Princess Margaret Canc |
|
| September 17, 2021 |
Regulation FD Disclosure, Financial Statements and Exhibits, Other Events UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of Earliest Event Reported): September 17, 2021 Deciphera Pharmaceuticals, Inc. (Exact name of registrant as specified in its charter) Delaware 001-38219 30-1003521 (State or other jurisdiction of incorporation) |
|
| September 17, 2021 |
Regulation FD Disclosure, Financial Statements and Exhibits, Other Events UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of Earliest Event Reported): September 17, 2021 Deciphera Pharmaceuticals, Inc. (Exact name of registrant as specified in its charter) Delaware 001-38219 30-1003521 (State or other jurisdiction of incorporation) |
|
| September 17, 2021 |
Exhibit 99.1 Deciphera Pharmaceuticals Presents New Clinical Study Results Across Pipeline at the European Society for Medical Oncology (ESMO) Congress 2021 ? Rebastinib in Combination with Paclitaxel Demonstrated Progression Free Survival of 9.1 months in Heavily Pretreated Patients with Platinum-Resistant Ovarian Cancer (PROC) ? ? Pivotal Phase 3 Study of Rebastinib plus Paclitaxel in PROC Plann |
|
| September 17, 2021 |
Exhibit 99.1 Deciphera Announces Positive CHMP Opinion for QINLOCK? for the Treatment of Fourth-line Gastrointestinal Stromal Tumor ? European Commission Decision Anticipated by the Fourth Quarter of 2021 ? Waltham, MA ? September 17, 2021 ? Deciphera Pharmaceuticals, Inc. (NASDAQ: DCPH), a commercial-stage biopharmaceutical company developing innovative medicines to improve the lives of people wi |
|
| September 17, 2021 |
Exhibit 99.2 A phase 1b/2 study of rebastinib and paclitaxel in advanced/metastatic platinum-resistant ovarian cancer Erika P Hamilton1, Sanjay Goel2, Rebecca Arend3, Christina Chu4, Debra L Richardson5, Bradley Corr6, Veena John7, Filip Janku8, John L Hays9, Mary Michenzie10, William Reichmann10, Haroun Achour10, Matthew L Sherman10, Rodrigo Ruiz-Soto10, Cara Mathews11 1Sarah Cannon Research Inst |
|
| August 3, 2021 |
Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of Earliest Event Reported): August 3, 2021 Deciphera Pharmaceuticals, Inc. (Exact name of registrant as specified in its charter) Delaware 001-38219 30-1003521 (State or other jurisdiction of incorporation) (Com |
|
| August 3, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ? QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2021 OR ? TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number: 00 |
|
| August 3, 2021 |
Exhibit 99.1 Deciphera Pharmaceuticals, Inc. Announces Second Quarter 2021 Financial Results - Second Quarter 2021 QINLOCK? Net Product Revenue of $22.0 Million - - Top-line Results from INTRIGUE Phase 3 Study of QINLOCK in Patients with Second-line Gastrointestinal Stromal Tumor (GIST) Expected in the Fourth Quarter of 2021 - - First Patient Treated in Phase 1 Study of ULK Kinase Inhibitor DCC-31 |
|
| June 25, 2021 |
Submission of Matters to a Vote of Security Holders UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of Earliest Event Reported): June 23, 2021 Deciphera Pharmaceuticals, Inc. (Exact name of registrant as specified in its charter) Delaware 001-38219 30-1003521 (State or other jurisdiction of incorporation) (Comm |
|
| May 4, 2021 |
Exhibit 99.1 Deciphera Pharmaceuticals, Inc. Announces First Quarter 2021 Financial Results - First Quarter 2021 QINLOCK? Net Product Revenue of $20.0 Million; QINLOCK Approved in China and Hong Kong for Fourth-line GIST - - Top-line Results from INTRIGUE Phase 3 Study of QINLOCK in Patients with Second-line GIST Expected in the Fourth Quarter of 2021; Plans to Initiate a Phase 1b/2 Study of QINLO |
|
| May 4, 2021 |
Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ? QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2021 OR ? TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number: 0 |
|
| May 4, 2021 |
Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of Earliest Event Reported): May 4, 2021 Deciphera Pharmaceuticals, Inc. (Exact name of registrant as specified in its charter) Delaware 001-38219 30-1003521 (State or other jurisdiction of incorporation) (Commis |
|
| April 29, 2021 |
Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) Filed by the Registrant ? Filed by a Party other than the Registrant ? Check the appropriate box: ? Preliminary Proxy Statement ? Confidential, for Use of the Commission Only (as permitted by Rule 14 |
|
| April 29, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) Filed by the Registrant ? Filed by a Party other than the Registrant ? Check the appropriate box: ? Preliminary Proxy Statement ? Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) ? Defin |
|
| March 31, 2021 |
EX-99.1 Exhibit 99.1 China NMPA Approves QINLOCK® (Ripretinib) for Treatment of Advanced Gastrointestinal Stromal Tumors (GIST) China NMPA approval follows 2020 U.S. FDA approval for the treatment of patients with fourth-line GIST QINLOCK demonstrated a significant improvement in progression-free survival and a clinically meaningful benefit in overall survival compared to placebo in the pivotal Ph |
|
| March 31, 2021 |
Regulation FD Disclosure, Financial Statements and Exhibits UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of Earliest Event Reported): March 31, 2021 Deciphera Pharmaceuticals, Inc. (Exact name of registrant as specified in its charter) Delaware 001-38219 30-1003521 (State or other jurisdiction of incorporation) (Com |
|
| February 16, 2021 |
Exhibit 99.1 Joint Filing Agreement In accordance with Rule 13d-1(k)(1) under the Securities Exchange Act of 1934, as amended (the “Exchange Act”), the undersigned hereby agree to the joint filing on behalf of each of them of a Statement on Schedule 13G (including any and all amendments thereto, the “Schedule 13G”) relating to the Common Stock, $0.01 par value per share, of Deciphera Pharmaceutica |
|
| February 16, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G/A Under the Securities Exchange Act of 1934 (Amendment No. 1) Deciphera Pharmaceuticals, Inc. (Name of Issuer) Common Stock, $0.01 par value (Title of Class of Securities) 24344T101 (CUSIP Number) December 31, 2020 (Date of Event Which Requires Filing of this Statement) Check the appropriate box to designate the r |
|
| February 10, 2021 |
SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Schedule 13G Under the Securities Exchange Act of 1934 Name of issuer: Deciphera Pharmaceuticals Inc. Title of Class of Securities: Common Stock CUSIP Number: 24344T101 Date of Event Which Requires Filing of this Statement: December 31, 2020 Check the appropriate box to designate the rule pursuant to which this Schedule is filed: ☒ Rule 13d |
|
| February 9, 2021 |
Exhibit 10.4 FORM OF NON-QUALIFIED STOCK OPTION AGREEMENT FOR COMPANY EMPLOYEES UNDER DECIPHERA PHARMACEUTICALS, INC. 2017 STOCK OPTION AND INCENTIVE PLAN Name of Optionee: No. of Option Shares: Option Exercise Price per Share: Grant Date: Expiration Date: Pursuant to the Deciphera Pharmaceuticals, Inc. 2017 Stock Option and Incentive Plan as amended through the date hereof (the “Plan”), Deciphera |
|
| February 9, 2021 |
Exhibit 10.7 FORM OF RESTRICTED STOCK UNIT AWARD AGREEMENT FOR NON-U.S. GRANTEES UNDER DECIPHERA PHARMACEUTICALS, INC. 2017 STOCK OPTION AND INCENTIVE PLAN Name of Grantee: No. of Restricted Stock Units: Grant Date: Pursuant to the Deciphera Pharmaceuticals, Inc. 2017 Stock Option and Incentive Plan as amended through the date hereof (the “Plan”), Deciphera Pharmaceuticals, Inc. (the “Company”) he |
|
| February 9, 2021 |
EX-99.1 Exhibit 99.1 Deciphera Pharmaceuticals, Inc. Announces Fourth Quarter and Full Year 2020 Financial Results - Fourth Quarter 2020 QINLOCK® Net Revenue of $19.5 Million and Full Year 2020 QINLOCK Net Revenue of $39.5 Million - - Top-line Results in INTRIGUE Phase 3 Study of QINLOCK in Patients with Second-line GIST Expected in the Second Half of 2021 - - Pipeline Candidates, Vimseltinib (DCC |
|
| February 9, 2021 |
Exhibit 10.5 FORM OF NON-QUALIFIED STOCK OPTION AGREEMENT FOR NON-U.S. OPTIONEES UNDER DECIPHERA PHARMACEUTICALS, INC. 2017 STOCK OPTION AND INCENTIVE PLAN Name of Optionee: No. of Option Shares: Option Exercise Price per Share: Grant Date: Expiration Date: Pursuant to the Deciphera Pharmaceuticals, Inc. 2017 Stock Option and Incentive Plan as amended through the date hereof (the “Plan”), Decipher |
|
| February 9, 2021 |
Exhibit 10.5 FORM OF RESTRICTED STOCK UNIT AWARD AGREEMENT FOR COMPANY EMPLOYEES UNDER DECIPHERA PHARMACEUTICALS, INC. 2017 STOCK OPTION AND INCENTIVE PLAN Name of Grantee: No. of Restricted Stock Units: Grant Date: Pursuant to the Deciphera Pharmaceuticals, Inc. 2017 Stock Option and Incentive Plan as amended through the date hereof (the “Plan”), Deciphera Pharmaceuticals, Inc. (the “Company”) he |
|
| February 9, 2021 |
Exhibit 10.17 EMPLOYMENT AGREEMENT This Employment Agreement (the “Agreement”) is made as of the 13th day of October, 2017, by and between Daniel L. Flynn, Ph.D. (the “Executive”) and Deciphera Pharmaceuticals, LLC, a Delaware limited liability company (the “Company”; the Executive and the Company are collectively referred to as the “Parties”). This Agreement shall be effective as of the closing o |
|
| February 9, 2021 |
S-8 As filed with the Securities and Exchange Commission on February 9, 2021 Registration No. |
|
| February 9, 2021 |
List of Subsidiaries of Registrant. Exhibit 21 DECIPHERA PHARMACEUTICALS, INC. The following is a list of significant subsidiaries of Deciphera Pharmaceuticals, Inc. as of December 31, 2020. SUBSIDIARY STATE OR OTHER JURISDICTION OF INCORPORATION OR ORGANIZATION Deciphera Pharmaceuticals, LLC Delaware Deciphera Pharmaceuticals Securities Corporation Massachusetts |
|
| February 9, 2021 |
Exhibit 10.16(a) AMENDMENT NO. 1 TO EMPLOYMENT AGREEMENT THIS AMENDMENT NO. 1 (“Amendment 1”) is made effective as of June 10, 2020 (“Amendment 1 Effective Date”) by and between Deciphera Pharmaceuticals, LLC with offices located at 200 Smith Street, Waltham, MA 02451 (“Company”) and Thomas P. Kelly ("Executive”). BACKGROUND. Company and Executive have entered into and executed an Employment Agree |
|
| February 9, 2021 |
Exhibit 10.17(a) AMENDMENT NO. 1 TO EMPLOYMENT AGREEMENT THIS AMENDMENT NO. 1 (“Amendment 1”) is made effective as of June 10, 2020 (“Amendment 1 Effective Date”) by and between Deciphera Pharmaceuticals, LLC with offices located at 200 Smith Street, Waltham, MA 02451 (“Company”) and Daniel L. Flynn, Ph.D. ("Executive”). BACKGROUND. Company and Executive have entered into and executed an Employmen |
|
| February 9, 2021 |
Exhibit 10.3 FORM OF INCENTIVE STOCK OPTION AGREEMENT UNDER THE DECIPHERA PHARMACEUTICALS, INC. 2017 STOCK OPTION AND INCENTIVE PLAN Name of Optionee: No. of Option Shares: Option Exercise Price per Share: Grant Date: Expiration Date: Pursuant to the Deciphera Pharmaceuticals, Inc. 2017 Stock Option and Incentive Plan as amended through the date hereof (the “Plan”), Deciphera Pharmaceuticals, Inc. |
|
| February 9, 2021 |
Exhibit 10.8 FORM OF NON-QUALIFIED STOCK OPTION AGREEMENT FOR NON-EMPLOYEE DIRECTORS UNDER DECIPHERA PHARMACEUTICS, INC. 2017 STOCK OPTION AND INCENTIVE PLAN Name of Optionee: No. of Option Shares: Option Exercise Price per Share: Grant Date: Expiration Date: Pursuant to the Deciphera Pharmaceuticals, Inc. 2017 Stock Option and Incentive Plan as amended through the date hereof (the “Plan”), Deciph |
|
| February 9, 2021 |
Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of Earliest Event Reported): February 9, 2021 Deciphera Pharmaceuticals, Inc. (Exact name of registrant as specified in its charter) Delaware 001-38219 30-1003521 (State or other jurisdiction of incorporation) (C |
|
| February 9, 2021 |
Employment Agreement, between Deciphera Pharmaceuticals, LLC and Stephen Ruddy Exhibit 10.20 EMPLOYMENT AGREEMENT This Employment Agreement (the "Agreement") is made as of the the day of , 2018, by and between Stephen Ruddy (the "Executive") and Deciphera Pharmaceuticals, LLC, a Delaware limited liability company (the "Company": the Executive and the Company are collectively referred to as the "Parties"). RECITALS WHEREAS, the Company desires to employ the Executive and the |
|
| February 9, 2021 |
Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K (Mark One) ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2020 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number: 001-38 |
|
| February 1, 2021 |
FOR SECTION 13 AND 16 REPORTING OBLIGATIONS SC 13G 1 deci20in.htm CUSIP NO. 24344T101 13G Page 1 of 14 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. )* DECIPHERA PHARMACEUTICALS, INC. (Name of Issuer) Common Stock, $0.01 Par Value Per Share (Title of Class of Securities) 24344T101 (CUSIP Number) December 31, 2020 (Date of Event Which Requires Fil |
|
| January 11, 2021 |
EX-99.1 Exhibit 99.1 Deciphera Pharmaceuticals Provides Corporate Update and Highlights Key 2021 Corporate Milestones - Top-line Data for INTRIGUE Pivotal Phase 3 Study of QINLOCK® in Patients with Second-line GIST Expected in the Second Half of 2021 - - Potential European Medicines Agency Approval of QINLOCK for Patients with Fourth-line GIST in the Second Half of 2021 - - Company Planning to Fin |
|
| January 11, 2021 |
Regulation FD Disclosure, Financial Statements and Exhibits - 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of Earliest Event Reported): January 11, 2021 Deciphera Pharmaceuticals, Inc. (Exact name of registrant as specified in its charter) Delaware 001-38219 30-1003521 (State or other jurisdiction of incorporation) (C |
|
| November 30, 2020 |
EX-99.1 Exhibit 99.1 Deciphera Pharmaceuticals Completes Target Enrollment in the INTRIGUE Phase 3 Clinical Study of QINLOCK® (Ripretinib) in Patients with Second-Line Gastrointestinal Stromal Tumor – Top-line Results Expected in Second Half of 2021 – – Study Designed to Evaluate the Efficacy and Safety Profile of QINLOCK Compared to Sunitinib in Patients Previously Treated with Imatinib – WALTHAM |
|
| November 30, 2020 |
Regulation FD Disclosure, Financial Statements and Exhibits, Other Events - 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of Earliest Event Reported): November 30, 2020 Deciphera Pharmaceuticals, Inc. (Exact name of registrant as specified in its charter) Delaware 001-38219 30-1003521 (State or other jurisdiction of incorporation) ( |
|
| November 12, 2020 |
Financial Statements and Exhibits, Other Events UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of Earliest Event Reported): November 11, 2020 Deciphera Pharmaceuticals, Inc. (Exact name of registrant as specified in its charter) Delaware 001-38219 30-1003521 (State or other jurisdiction of incorporation) ( |
|
| November 12, 2020 |
EX-99.1 Exhibit 99.1 Exhibit 99.1 CTOS Annual Meeting, Nov 18–21, 2020 Phase 1 Dose-Escalation Study of the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of DCC-3014 in Advanced Solid Tumors and Tenosynovial Giant Cell Tumor (TGCT) (NCT3069469) Albiruni Abdul Razak1, Breelyn A. Wilky2, Jacqueline Vuky3, Lara E.Davis3, Todd Bauer4, Hans Gelderblom5, Mary Michenzie6, Maitreyi Sharma6, |
|
| November 5, 2020 |
Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2020 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file numbe |
|
| November 5, 2020 |
EX-99.1 Exhibit 99.1 Deciphera Pharmaceuticals, Inc. Announces Third Quarter 2020 Financial Results – U.S. QINLOCK® Net Revenue of $14.7 Million in the First Full Quarter of Launch – – Marketing Authorisation Application for QINLOCK in Fourth-line GIST Validated by the European Medicines Agency; Commercial Planning for Europe Underway – – Enrollment for QINLOCK Phase 3 INTRIGUE Study Expected to b |
|
| November 5, 2020 |
Financial Statements and Exhibits, Results of Operations and Financial Condition - 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of Earliest Event Reported): November 5, 2020 Deciphera Pharmaceuticals, Inc. (Exact name of registrant as specified in its charter) Delaware 001-38219 30-1003521 (State or other jurisdiction of incorporation) (C |
|
| August 4, 2020 |
Entry into a Material Definitive Agreement, Financial Statements and Exhibits 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): August 4, 2020 DECIPHERA PHARMACEUTICALS, INC. (Exact name of registrant as specified in its charter) Delaware 001-38219 30-1003521 (State or other jurisdiction of Incorporation) |
|
| August 4, 2020 |
424B5 Table of Contents As Filed Pursuant to Rule 424(b)(5) File No. 333-236389 CALCULATION OF REGISTRATION FEE Title of Each Class of Securities to be Registered Proposed Maximum Aggregate Offering Price Amount of Registration Fee Common Stock, par value $0.01 per share $200,000,000 $25,960(1) (1) Calculated in accordance with Rule 457(o) under the Securities Act of 1933, as amended. This “Calcul |
|
| August 4, 2020 |
EX-10.1 Exhibit 10.1 OPEN MARKET SALE AGREEMENTSM August 4, 2020 JEFFERIES LLC 520 Madison Avenue New York, New York 10022 Ladies and Gentlemen: Deciphera Pharmaceuticals, Inc., a Delaware corporation (the “Company”), proposes, subject to the terms and conditions stated herein, to issue and sell from time to time through Jefferies LLC, as sales agent and/or principal (the “Agent”), shares of the C |
|
| August 4, 2020 |
Exhibit 10.1 Execution version CERTAIN CONFIDENTIAL PORTIONS OF THIS EXHIBIT HAVE BEEN OMITTED AND REPLACED WITH “[***]”. SUCH IDENTIFIED INFORMATION HAS BEEN EXCLUDED FROM THIS EXHIBIT BECAUSE IT IS (I) NOT MATERIAL AND (II) WOULD LIKELY CAUSE COMPETITIVE HARM TO THE COMPANY IF DISCLOSED. COMMERCIAL MANUFACTURING SERVICES AND SUPPLY AGREEMENT This Commercial Manufacturing Services and Supply Agre |
|
| August 4, 2020 |
EX-99.1 Exhibit 99.1 Deciphera Pharmaceuticals, Inc. Announces Second Quarter 2020 Financial Results - QINLOCKTM Approved for the Treatment of Fourth-Line Gastrointestinal Stromal Tumor and U.S. Commercial Launch Underway - - Reported QINLOCK Net Revenue of $4.8 Million in the First Partial Quarter of Launch - - Company Expects to Complete Enrollment in Phase 3 INTRIGUE Study in Fourth Quarter 202 |
